Emergence of Macrolide-Resistant Mycoplasma pneumoniae with a 23S rrna Gene Mutation
|
|
- Kerry Walters
- 5 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2005, p Vol. 49, No /05/$ doi: /aac Copyright 2005, American Society for Microbiology. All Rights Reserved. Emergence of Macrolide-Resistant Mycoplasma pneumoniae with a 23S rrna Gene Mutation Miyuki Morozumi, 1 Keiko Hasegawa, 1 Reiko Kobayashi, 1 Nagako Inoue, 2 Satoshi Iwata, 3 Haruo Kuroki, 4 Naohisa Kawamura, 5 Eiichi Nakayama, 6 Takeshi Tajima, 6 Kouichi Shimizu, 7 and Kimiko Ubukata 1 * Laboratory of Infectious Agents Surveillance, Kitasato Institute for Life Sciences, Kitasato University, Shirokane, Minatoku, Tokyo, Japan 1 ; Kitasato Institute for Life Sciences & Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan 2 ; National Hospital Organization Tokyo Medical Center, Tokyo, Japan 3 ; Medical Corporation Nagatsu-kai Saito Hospital, Chiba, Japan 4 ; Osaka Rosai Hospital, Osaka, Japan 5 ; Hakujikai Memorial Hospital, Tokyo, Japan 6 ; and Saiseikai Ibaraki Hospital, Osaka, Japan 7 Received 7 October 2004/Returned for modification 5 December 2004/Accepted 31 January 2005 A total of 195 Mycoplasma pneumoniae strains were isolated from 2,462 clinical specimens collected between April 2002 and March 2004 from pediatric outpatients with respiratory tract infections. Susceptibilities to six macrolide antibiotics (ML), telithromycin, minocycline, levofloxacin, and sitafloxacin were determined by the microdilution method using PPLO broth. A total of 183 M. pneumoniae isolates were susceptible to all agents and had excellent MIC 90 s in the following order: g/ml for azithromycin and telithromycin, g/ml for clarithromycin, g/ml for erythromycin, g/ml for sitafloxacin, 0.5 g/ml for minocycline, and 1 g/ml for levofloxacin. Notably, 12 ML-resistant M. pneumoniae strains were isolated from patients with pneumonia (10 strains) or acute bronchitis (2 strains). These strains showed resistance to ML with MICs of >1 g/ml, except to rokitamycin. Transition mutations of A2063G or A2064G, which correspond to A2058 and A2059 in Escherichia coli, in domain V on the 23S rrna gene in 11 ML-resistant strains were identified. By pulsed-field gel electrophoresis typing, these strains were classified into groups I and Vb, as described previously (A. Cousin-Allery, A. Charron, B. D. Barbeyrac, G. Fremy, J. S. Jensen, H. Renaudin, and C. Bebear, Epidemiol. Infect. 124: , 2000). These findings suggest that excessive usage of MLs acts as a trigger to select mutations on the corresponding 23S rrna gene with the resultant occurrence of MLresistant M. pneumoniae. Monitoring ML susceptibilities for M. pneumoniae is necessary in the future. * Corresponding author. Mailing address: Laboratory of Infectious Agents Surveillance, Kitasato Institute for Life Sciences, Kitasato University, Shirokane, Minatoku, Tokyo, Japan. Phone: Fax: ubukatak@lisci.kitasato -u.ac.jp. Mycoplasma pneumoniae is one of the main pathogens in respiratory tract infections (RTI) acquired in the community. In school-aged children and young adults with communityacquired pneumonia (CAP), M. pneumoniae accounts for as many as 10 to 30% of cases (4, 6, 13). In recent years, the clinical diagnosis for M. pneumoniae infection has relied on serological methods such as passive agglutination (Serodia-Myco II kit, Fujirebio, Tokyo, Japan) and complement fixation, even though a PCR method was partially applied (3, 22, 26). Accordingly, culture methods for this pathogen that require up to 1 week or more are rarely carried out in the laboratory. Thus, the current status of susceptibility to macrolide antibiotics (ML) used as the firstchoice agent for M. pneumoniae is unclear. In Japan, in parallel with the increase in usage of oral 14- membered ring ML (14-ML) and azithromycin for RTI, M. pneumoniae showing resistance to 14-ML has been isolated from clinical samples from pediatric outpatients with CAP (12, 16). We suspected an increase in cases with ML-resistant M. pneumoniae infection from prolonged clinical symptoms. In such cases, PCR positivity with rapid identification of M. pneumoniae persisted after the administration of clarithromycin or azithromycin for several days. We isolated causative M. pneumoniae by cultivation from clinical specimens collected from pediatric outpatients with RTI to determine susceptibilities to 10 oral antibiotics and identified a transition mutation on the 23S rrna gene in ML-resistant isolates. MATERIALS AND METHODS Microorganisms. M. pneumoniae was isolated from clinical specimens from patients with RTI. The specimens were collected from pediatric outpatients who visited 10 medical Japanese institutions participating in the study group on acute respiratory diseases (ARD). A total of 2,462 samples were sent to our laboratory (Kitasato Institute for Life Sciences, Kitasato University) between April 2002 and March Rapid detection by PCR for M. pneumoniae was performed initially using a primer set constructed on the 16S rrna gene and methods described previously (14). Cultivation of M. pneumoniae was carried out for 262 PCR-positive specimens with PPLO broth and agar plates. Composition of the broth was as follows: 70 ml PPLO broth (Difco, Inc., Detroit, Mich.) supplemented with 20 ml horse serum, 5 ml 50% yeast extract, 2.5 ml 20% glucose, 200 l 1% phenol red, 1 ml 2.5% thallium acetate, 0.5 ml 200,000 units/ml potassium penicillin G, and 0.5 ml 20,000 g/ml cefotaxime. M. pneumoniae was identified by a change in the color of the broth from red to yellow, by the resulting utilization of glucose, and by hemadsorption when colonies were overlaid with a 5% suspension of guinea pig erythrocytes. Incubation of PPLO broth and agar plates was performed according to previously described methods (25). M. pneumoniae strains isolated after purification procedures were stored at 80 C until use. Antibiotic susceptibility testing. MICs of 10 agents for M. pneumoniae strains were determined by microdilution methods with PPLO broth (17, 21). The Downloaded from on November 17, 2018 by guest 2302
2 VOL. 49, 2005 MACROLIDE-RESISTANT M. PNEUMONIAE 2303 TABLE 1. Primers used in this study Primer target Primer name Sequence Nucleotide position 16S rrna Mpn-S 5 -GTAATACTTTAGAGGCGAACG Mpn-R 5 -TACTTCTCAGCATAGCTACAC Product size (bp) 23S rrna Mp-1S 5 -GTTACTAAGGGCTTATGGTG ,583 Mp-1R 5 -GATTAATACCACCTTCGCTAC Mp-2S 5 -GGACAACAGGTTAATATTCCTG ,498 Mp-2R 5 -CAATAAGTCCTCGAGCAATTAG following agents were provided by the indicated manufacturer: erythromycin (Shionogi Pharmaceutical Co., Ltd., Osaka, Japan), clarithromycin (Taisho Pharmaceutical Co., Ltd., Tokyo, Japan), josamycin (Yamanouchi Pharmaceutical Co., Ltd., Tokyo, Japan), midecamycin (Meiji Seika Kaisha, Ltd., Tokyo, Japan), rokitamycin (Asahi Kasei Co., Tokyo, Japan), azithromycin (Pfizer Japan, Inc., Tokyo, Japan), telithromycin (Aventis Pharma, Ltd., Bridgewater, N.J.), minocycline (Wyeth Japan, Tokyo, Japan), and levofloxacin and sitafloxacin (Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan). M. pneumoniae strain M129 was used as a control. After approximately 30 l of each M. pneumoniae suspension was inoculated into 1.5 ml of PPLO broth, and the inoculates were subcultured for 4 to 5 days at 37 C until they changed to a yellow color. Each 10 l of the culture, estimated to be 10 5 CFU/ml of M. pneumoniae, was inoculated into 96-well microplates with 90 l of PPLO broth, which contained serially diluted antibiotics. The microplate was sealed and incubated aerobically for 14 days at 37 C until color change in the antibiotic-free growth control was confirmed. The MIC was defined as the lowest concentration of each antibiotic without color change. Sequencing. The total length of the 23S rrna gene in 12 M. pneumoniae strains showing ML resistance was sequenced by methods described previously (24). Two primer sets shown in Table 1 were used for amplification of the entire 23S rrna gene. The sequencing reaction was conducted with a DYEnamic ET Terminator Cycle Sequencing kit (Amersham Pharmacia Biotech, Piscataway, N.J.). The nucleotide sequences were determined with an ABI PRISM 377 DNA sequencer, and the results were compared to the genome sequence (8) and to ML-resistant strains (12, 16). Genes encoding ribosomal proteins L4 and L22, respectively, were sequenced using primers described by Pereyre et al. (17). PFGE typing. Pulsed-field gel electrophoresis (PFGE) typing was carried out by a modification of the methods of Hasegawa et al. (7). M. pneumoniae grown in 5 ml PPLO broth for 5 to 7 days was harvested by centrifugation at 12,000 rpm at 4 C for 30 min, followed by three washes with saline-edta solution. After cells were resuspended in Pet IV solution (1 M NaCl, 10 mm EDTA), 1.6 this volume of melted 2.0% low-melting-point agarose was added (InCert agarose; FMC Bioproducts, Rockland, Maine). The mixture was poured into an insert mold and chilled at 4 C for 20 min. Plugs removed from the mold were treated with 0.2 mg proteinase K (Sigma Chemical Co., St. Louis, Mo.) per ml in ES solution (0.25 M EDTA [ph 8.0], 1% Sarkosyl) at 50 C for 17 h. The ES solution was decanted, and the plugs were placed in TE buffer (10 mm Tris-HCl [ph 8.0], and 1 mm EDTA[pH 8.0] containing 1 mm phenylmethylsulfonyl fluoride) at room temperature for 3 h. The plugs were washed three times in TE buffer for 15 min at room temperature and placed in TE buffer (10 mm Tris-HCl [ph 8.0], 0.1 mm EDTA [ph 8.0]). For restriction endonuclease digestion, the plugs were incubated in restriction enzyme buffer for 30 min at room temperature to remove EDTA and then incubated in restriction enzyme buffer with 20 U of ApaI at 37 C for 16 h. Electrophoresis was performed using a CHEF Mapper (Bio-Rad Laboratories, Hercules, Calif.). Separation of fragments was carried out at 5.7 V/cm at 14 C for 18 h. RESULTS Clinical isolates of M. pneumoniae. PCR detection of M. pneumoniae was routinely conducted on all clinical specimens, such as nasopharyngeal and pharyngeal secretions and sputum collected from pediatric outpatients with RTI. Cultivation of M. pneumoniae was only carried out with PCR-positive samples. As shown in Table 2, 195 M. pneumoniae strains were isolated from 2,462 subjects. Almost all isolates were from cases of pneumonia (169 isolates; 86.7%) and then acute bronchitis (19 isolates; 9.7%). The remaining were isolates from acute otitis media, upper respiratory tract infection, and acute tonsillitis cases. Susceptibility to 10 agents for M. pneumoniae. MICs in this study were determined for erythromycin and clarithromycin of the 14-ML; josamycin, midecamycin, and rokitamycin of 16- membered ring ML (16-ML); azithromycin of azalides; telithromycin of ketolides; minocycline; levofloxacin; and sitafloxacin. Table 3 shows the results of 183 M. pneumoniae strains that were susceptible to ML, together with the results of the control M129 strain. The MIC 90 s of each agent for these strains were excellent, in the following order: g/ml for azithromycin and telithromycin, g/ml for clarithromycin, g/ml for erythromycin and rokitamycin, g/ml for sitafloxacin and josamycin, g/ml for midecamycin, 0.5 g/ml for minocycline, and 1 g/ml for levofloxacin. Table 4 shows the MICs of all agents for 12 M. pneumoniae strains classified as ML resistant. The strains showed high resistance for erythromycin, clarithromycin, and azithromycin with MICs of 32 g/ml. The MICs of telithromycin, josamycin, and midecamycin ranged from 2 to 64 g/ml, except for the ARD-185 strain. Only rokitamycin of the 16-ML had good MICs for these resistant strains, ranging from g/ml to 16 g/ml. The MICs of minocycline, levofloxacin, and sitafloxacin were the same as for ML-susceptible strains. Of the 12 strains, 10 originated from pneumonia cases and 2 originated from bronchitis cases. TABLE 2. Diseases and M. pneumoniae-positive cases in pediatric outpatients Disease Cases (n) No. (%) PCR positive M. pneumoniae No. (%) culture positive Pneumonia 1, (18.4) 169 (14.3) Acute bronchitis (5.0) 19 (3.3) Acute upper respiratory (0.6) 2 (0.6) infection Acute tonsillitis (3.5) 1 (0.6) Acute otitis media 63 1 (1.6) 1 (1.6) Other (4.4) 3 (2.2) Total 2, (10.6) 195 (7.9) Downloaded from on November 17, 2018 by guest
3 2304 MOROZUMI ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 3. In vitro antimicrobial activity of 10 oral agents against macrolide-susceptible Mycoplasma pneumoniae strains (n 183) Antibiotic MIC ( g/ml) Range 50% 90% M129 a Erythromycin Clarithromycin Azithromycin Josamycin Midecamycin Rokitamycin Telithromycin Minocycline Levofloxacin Sitafloxacin a Standard strain. Mutation on the 23S rrna gene in ML-resistant M. pneumoniae. The full-length 23S rrna gene (8) in ML-resistant M. pneumoniae strains was sequenced, and the results of the transition mutation on the gene are shown in Table 4 along with MICs. Nine strains had an A2063G transition in domain V, and two strains had an A2064G transition. All these strains had no C785 transition in domain II. MICs of telithromycin for the latter strains were 2 g/ml and 4 g/ml, obviously different from strains with the A2063G transition. The strain numbered ARD-185 had no transition in the 23S rrna gene. No mutation that effects to amino acid substitution was identified on each gene encoding ribosomal proteins L4 and L22 (data not shown). PFGE typing. PFGE typing was performed on ML-susceptible strains selected randomly in addition to all ML-resistant strains. Figure 1 shows the results of those and M129 strain as a control digested by the ApaI restriction enzyme. All strains were classified into two groups, group I and subgroup IIb, as described by Cousin-Allery et al. (2). Of the 12 ML-resistant strains, 7 belonged in group I, and 5 belonged in subgroup IIb (Fig. 1 and Table 4). The ML-resistant strains were isolated from three different areas (Tokyo, Osaka, and Chiba, Japan). The difference in PFGE patterns was not recognized between samples from different areas. Strain DISCUSSION M. pneumoniae is a common etiologic agent of RTI in communities, particularly in school-aged children and young adults. This agent accounts for 10 to 30% of CAPs (4, 6, 13). Generally, 14-ML and azithromycin have been prescribed as first-choice agents for CAP and RTI due to M. pneumoniae when pathogen-specific therapy is used. Minocycline and fluoroquinolones may be used as alternatives. Recently, telithromycin of the ketolide compounds, a new class of antimicrobial agent, has been developed based on resistance to ML in S. pneumoniae (1, 19). The chemical structure of telithromycin is characterized by a ketone group at the 3-position, a methyoxy group at the 6-position, and an alkyl/ aryl extension from carbamate group at positions 11 and 12 (5, 18), which prevents methylation of 23S rrna by methylase in ML-resistant strains. Telithromycin had excellent MICs of to 0.25 g/ml for ML-resistant S. pneumoniae possessing resistant determinants (23) and has been introduced clinically. Meanwhile, ML-resistant M. pneumoniae was first isolated in 2000 from a 9-year-old girl with pneumonia (12, 16). These results suggest emergence of ML-resistant M. pneumoniae in Japan, not yet reported worldwide. As described in the results, 93.8% of M. pneumoniae strains showed excellent susceptibilities to 14-ML, azithromycin, and telithromycin with MIC 90 s ranging from to g/ ml. However, 12 (6.2%) ML high-resistance M. pneumoniae strains were detected in this study. These cause clinical problems, since concentrations that overcome high resistance are not attainable by oral administration. ML-resistant M. pneumoniae has been known for more than 20 years, although the mechanisms of resistance have been uncertain (15, 20). Transition mutations identified on the 23S rrna gene in resistant strains were reported previously by Lucier et al. (11) using the M129 standard strain for in vitro mutation experiments; mutations at A2063G and A2064G in domain V correspond to A2058 and A2059 in Escherichia coli (18), respectively. All but one strain tested showed resistance, not only for 14-ML and azithromycin but also for all 16-MLs except rokitamycin, which has been developed in Japan and TABLE 4. In vitro antimicrobial activity of 10 agents against macrolide-resistant Mycoplasma pneumoniae strains (n 12) Patient age (yr) MIC ( g/ml) a ERY CLR AZM TEL JOS MDM RKI MIN LVX SFX Nucleotide changes, 23S rrna b ARD A2063G IIb ARD None IIb ARD A2063G IIb ARD A2063G I ARD A2063G I ARD A2064G I ARD A20634 I ARD A2063G IIb ARD A2063G I ARD A2063G I ARD A2064G IIb ARD A2063G I PFGE pattern c Downloaded from on November 17, 2018 by guest a ERY, erythromycin; CLR, clarithromycin; AZM, azithromycin; TEL, telithromycin; JOS, josamycin; MDM, midecamycin; RKI, rokitamycin; MIN, minocycline; LVX, levofloxacin; SFX, sitafloxacin (DU-6859a). b M. pneumoniae numbering. c PFGE typing was classified into group I and subgroup II b as described by Cousin-Allery et al. (2).
4 VOL. 49, 2005 MACROLIDE-RESISTANT M. PNEUMONIAE 2305 FIG. 1. Pulsed-field gel electrophoresis patterns generated by ApaI digestion of Mycoplasma pneumoniae strains. M129, reference strain; strain numbers ARD-1940 to ARD-2323, ML resistance (ML r ); strain numbers ARD-11 to ARD-1987, ML susceptible (ML s ); M, marker of lambda ladder. used in a few countries in Asia. From the current understanding of the mechanism of ML resistance, we speculate that telithromycin resistance is as follows: A784 detected in domain II of S. pneumoniae (9), which is supposed to be necessary for the expression of activity, was originally C785 in M. pneumoniae. This position in domain II in M. pneumoniae also corresponds to A752 in E. coli (18). The resistance mechanism in one strain, ARD185, is unknown, so further studies will be necessary. Molecular typing by PFGE for M. pneumoniae has been carried out with isolates from two countries (2). These isolates were classified into two groups, group I and group II, with subgroups IIa and IIb. As shown in Fig. 1, all strains tested by PFGE typing belonged to either group I or group IIb, and ML-resistant strains were confirmed in both groups. These findings suggest that ML-resistant M. pneumoniae isolates may gradually be increasing in parallel with the increase in number of ML prescriptions to outpatients. The expansion of 14-ML, azithromycin, and telithromycin usage for RTI worldwide may increase ML-resistant M. pneumoniae. Further evaluation for new quinolones, such as sparfloxacin (10) and sitafloxacin, will be necessary in vivo and in vitro. Although clinical symptoms appeared to be prolonged in patients with ML-resistant M. pneumoniae infections, their clinical course will be described in another paper. In conclusion, studies are needed to clarify the prevalence of ML-resistant M. pneumoniae in adults and monitoring of global trends. ACKNOWLEDGMENTS This work was supported in part by two grants, one from the Meiji Seika Kaisha and one from the Japanese Ministry of Education, Culture, Sport, Science and Technology (the 21st Century COE program). REFERENCES 1. Bryskier, A., C. Agouridas, and J. F. Chantot Ketolides: new semisynthetic 14-membered-ring macrolides, p In S. H. Zinner, L. S. Young, J. F. Acar, H. C. Neu (ed.), Expanding indications for the new macrolides, azalides, and streptogramins. Marcel Dekker, Inc., New York, N.Y. 2. Cousin-Allery, A., A. Charron, B. D. Barbeyrac, G. Fremy, J. S. Jensen, H. Renaudin, and C. Bebear Molecular typing of Mycoplasma pneumoniae strains by PCR-based methods and pulsed-field gel electrophoresis. Application to French and Danish isolates. Epidemiol. Infect. 124: Dorigo-Zetsma, J. W., S. A. J. Zaat, P. M. E. Wertheim-van Dillen, L. Spanjaard, J. Rijntjes, G. van Waveren, J. S. Jensen, A. F. Angulo, and J. Dankert Comparison of PCR, culture, and serological tests for diagnosis of Mycoplasma pneumoniae respiratory tract infection in children. J. Clin. Microbiol. 37: Hammerschlag, M. R Mycoplasma pneumoniae infections. Curr. Opin. Infect. Dis. 14: Hansen, L. H., P. Mauvais, and S. Douthwaite The macrolide-ketolide antibiotic binding site is formed by structures in domain II and V of 23S ribosomal RNA. Mol. Microbiol. 31: Harris, J. A., A. Kolokathis, M. Campbell, G. H. Cassell, and M. R. Hammerschlag Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr. Infect. Dis. J. 17: Hasegawa, K., N. Chiba, R. Kobayashi, S. Y. Murayama, S. Iwata, K. Su- Downloaded from on November 17, 2018 by guest
5 2306 MOROZUMI ET AL. ANTIMICROB. AGENTS CHEMOTHER. nakawa, and K. Ubukata Rapidly increasing prevalence of -lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae type b in patients with meningitis. Antimicrob. Agents Chemother. 48: Himmelreich, R., H. Hilbert, H. Plagens, E. Pirkl, B. C. Li, and R. Herrmann Complete sequence analysis of the genome of the bacterium Mycoplasma pneumoniae. Nucleic Acids Res. 24: Hoskins, J., W. E. Alborn, Jr., J. Arnold, L. C. Blaszczak, S. Burgett, B. S. DeHoff, S. T. Estrem, L. Fritz, D. J. Fu, W. Fuller, C. Geringer, R. Gilmour, J. S. Glass, H. Khoja, A. R. Kraft, R. E. Lagace, D. J. LeBlanc, L. N. Lee, E. J. Lefkowitz, J. Lu, P. Matsushima, S. M. McAhren, M. McHenney, K. McLeaster, C. W. Mundy, T. I. Nicas, F. H. Norris, M. O Gara, R. B. Peery, G. T. Robertson, P. Rockey, P. M. Sun, M. E. Winkler, Y. Yang, M. Young- Bellido, G. Zhao, C. A. Zook, R. H. Baltz, S..R. Jaskunas, P. R. Rosteck, Jr., P. L. Skatrud, and J. I. Glass Genome of the bacterium Streptococcus pneumoniae strain R6. J. Bacteriol. 183: Kaku, M., K. Ishida, K. Irifune, R. Mizukane, H. Takemura, R. Yoshida, H. Tanaka, T. Utsui, K. Tomono, N. Suyama, H. Koga, S. Kohno, and K. Hara In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 38: Lucier, T. S., K. Heitzman, S.-K. Liu, and P.-C. Hu Trasition mutations in the 23S rrna of erythromycin-resistant isolates of Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 39: Matsuoka, M., M. Narita, N. Okazaki, H. Ohya, T. Yamazaki, K. Ouchi, I. Suzuki, T. Andoh, T. Kenri, Y. Sasaki, A. Horino, M. Shintani, Y. Arakawa, and T. Sasaki Characterization and molecular analysis of macrolideresistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob. Agents Chemother. 48: McIntosh, K Community-acquired pneumonia in children. N. Engl. J. Med. 346: Morozumi, M., K. Hasegawa, N. Chiba, S. Iwata, N. Kawamura, H. Kuroki, T. Tajima, and K. Ubukata Application of PCR for Mycoplasma pneumoniae detection in children with community-acquired pneumonia. J. Infect. Chemother. 10: Niitu, Y., S. Hasegawa, T. Suetake, H. Kubota, S. Komatsu, and M. Horikawa Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics. J. Pediatr. 76: Okazaki, N., M. Narita, S. Yamada, K. Izumikawa, M. Umetsu, T. Kenri, Y. Sasaki, Y. Arakawa, and T. Sasaki Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol. Immunol. 45: Pereyre, S., C. Guyot, H. Renaudin, A. Charron, C. Bébéar, and C. M. Bébéar In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 48: Poehlsgaard, J., and S. Douthwaite Macrolide antibiotic interaction and resistance on the bacterial ribosome. Curr. Opin. Investig.Drugs 4: Rosato, A., H. Vicarini, A. Bonnefoy, J. F. Chantot, and R. Leclercq A new ketolide, HMR3004, active against streptococci inducibility resistant to erythromycin. Antimicrob. Agents Chemother. 42: Stopler, T., and D. Branski Resistance of Mycoplasma pneumoniae to macrolides, lincomycin and streptogramin B. J. Antimicrob. Chemother. 18: Takahata, M., M. Shimakura, R. Hori, K. Kizawa, Y. Toda, S. Minami, Y. Watanabe, and H. Narita In vitro and in vivo efficacies of T-3811ME (BMS ) against Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 45: Templeton, K. E., S. A. Scheltinga, A. W. Graffelman, J. M. van Schie, J. W. Crielaard, P. J. van den Broek, H. Goossens, M. F. C. Beersma, and E. C. J. Claas Comparison and evaluation of real-time PCR, real-time nucleic acid sequence-based amplification, conventional PCR, and serology for diagnosis of Mycoplasma pneumoniae. J. Clin. Microbiol. 41: Ubukata, K., S. Iwata, and K. Sunakawa In vitro activities of new ketolide, telithromycin, and eight other macrolide antibiotics against Strptococcus pneumoniae having mefa and ermb genes that mediate macrolide resistance. J. Infect. Chemother. 9: Ubukata, K., Y. Shibasaki, K. Yamamoto, N. Chiba, K. Hasegawa, Y. Takeuchi, K. Sunakawa, M. Inoue, and M. Konno Association of amino acid substitutions in penicillin-binding protein 3 with -lactam resistance in -lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob. Agents Chemother. 45: Waites, K. B., Y. Rikihisa, and D. Taylor-Robinson Mycoplasma and ureaplasma, p In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken (ed.), Manual of clinical microbiology, 8 th ed. ASM Press, Washington, D.C. 26. Welti, M., K. Jaton, M. Altwegg, R. Sahli, A. Wenger, and J. Bille Development of a multiplex real-time quantitative PCR assay to detect Chlamydia pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae in respiratory tract secretions. Diagn. Microbiol. Infect. Dis. 45: Downloaded from on November 17, 2018 by guest
6 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 2005, p Vol. 49, No /05/$ doi: /aac ERRATUM Emergence of Macrolide-Resistant Mycoplasma pneumoniae with a 23S rrna Gene Mutation Miyuki Morozumi, Keiko Hasegawa, Reiko Kobayashi, Nagako Inoue, Satoshi Iwata, Haruo Kuroki, Naohisa Kawamura, Eiichi Nakayama, Takeshi Tajima, Kouichi Shimizu, and Kimiko Ubukata Laboratory of Infectious Agents Surveillance, Kitasato Institute for Life Sciences, Kitasato University, Shirokane, Minatoku, Tokyo, Japan; Kitasato Institute for Life Sciences & Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan; National Hospital Organization Tokyo Medical Center, Tokyo, Japan; Medical Corporation Nagatsu-kai Saito Hospital, Chiba, Japan; Osaka Rosai Hospital, Osaka, Japan; Hakujikai Memorial Hospital, Tokyo, Japan; and Saiseikai Ibaraki Hospital, Osaka, Japan Volume 49, no. 6, p , Page 2302, line 11 of the abstract: groups I and Vb should read groups I and IIb. Page 2304, Table 4: In the Nucleotide changes column, the entry A2064G for strain ARD-2000 should read A2063G and the entry A20634 for strain ARD-2081 should read A2064G. 3100
S. Pereyre,* A. Charron, H. Renaudin, C. Bébéar, and C. M. Bébéar
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2007, p. 3534 3539 Vol. 45, No. 11 0095-1137/07/$08.00 0 doi:10.1128/jcm.01345-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. First Report
More informationMycoplasma pneumoniae 23S rrna Gene Mutations and Mechanisms of Macrolide Resistance
Mycoplasma pneumoniae 23S rrna Gene Mutations and Mechanisms of Macrolide Resistance Yun Ye, MS,* Suliang Li, MS, Yajun Li, PhD, Tianshun Ren, MS, and Kaige Liu, PhD ABSTRACT Objective: Resistant strains
More informationSimultaneous and Rapid Detection of Causative Pathogens in Community-acquired Pneumonia by Real-time PCR (1167)
From the Japanese Association of Medical Sciences The Japanese Association for Infectious Diseases Simultaneous and Rapid Detection of Causative Pathogens in Community-acquired Pneumonia by Real-time PCR
More informationMulti-clonal origin of macrolide-resistant Mycoplasma pneumoniae isolates. determined by multiple-locus variable-number tandem-repeat analysis
JCM Accepts, published online ahead of print on 30 May 2012 J. Clin. Microbiol. doi:10.1128/jcm.00678-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Multi-clonal origin
More information- Mycoplasma pneumoniae (MP): important respiratory pathogen in children that cause many upper and lower respiratory tract diseases, including
KHOA DICH VU HO HAP - Mycoplasma pneumoniae (MP): important respiratory pathogen in children that cause many upper and lower respiratory tract diseases, including wheezing, coryza, bronchopneumonia. -
More information/01/$ DOI: /AAC Copyright 2001, American Society for Microbiology. All Rights Reserved.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2001, p. 2604 2608 Vol. 45, No. 9 0066-4804/01/$04.00 0 DOI: 10.1128/AAC.45.9.2604 2608.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.
More informationGAS surveillance. emm12 emm28 emm89 GAS GAS. A GAS Streptococcus pyogenes GAS GAS PSAGN GAS GAS. emm. Vol. 26 No GAS surveillance study group
014 Vol. 6No. 11 A 1 1 GAS surveillance study group A GAS GAS surveillance study group01 GAS 44 PCR 60 GAS emm emm8emm8 GAS emm GAS A GASStreptococcus pyogenes GAS 1 6 1 GAS 1, GAS GAS GAS PSAGN GAS Key
More informationGuiding principles* for treating Mycoplasma pneumoniae pneumonia
1 Guiding principles* for treating Mycoplasma pneumoniae pneumonia The Committee of Japanese Society of Mycoplasmology Shigeru Kohno (Chair, Nagasaki University) Tadashi Ishida (Kurashiki Central Hospital)
More informationCharacterization and Molecular Analysis of Macrolide-Resistant Mycoplasma pneumoniae Clinical Isolates Obtained in Japan
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2004, p. 4624 4630 Vol. 48, No. 12 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.12.4624 4630.2004 Copyright 2004, American Society for Microbiology. All Rights
More informationtelithromycin oral streptococci 140 telithromycin TEL azithromycin AZM clarithromycin CAM roxithromycin RXM levofloxacin LVFX ampicillin ABPC
telithromycin 3 0 3 0 oral streptococci 0 telithromycintelazithromycin AZMclarithromycinCAMroxithromycinRXMlevofloxacinLVFXampicillinABPC erythromycinem TEL EM erm mef 5 Streptococcus mitis MIC90 ml TEL
More informationAssessment of real-time PCR for diagnosis of Mycoplasma pneumoniae pneumonia in pediatric patients
Assessment of real-time PCR for diagnosis of Mycoplasma pneumoniae pneumonia in pediatric patients Miyuki Morozumi, Akira Ito, Somay Y. Murayama, Keiko Hasegawa, Reiko Kobayashi, Satoshi Iwata, Naohisa
More informationPharmacokinetics of the New Ketolide Telithromycin (HMR 3647) Administered in Ascending Single and Multiple Doses
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2001, p. 170 175 Vol. 45, No. 1 0066-4804/01/$04.00 0 DOI: 10.1128/AAC.45.1.170 175.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.
More informationStreptococcus pneumoniae 356 moxifloxacin (MFLX), garenoxacin (GRNX) sitafloxacin
2009 21 1) 1, 2) 1, 2) 1) 1) 2) 1) 1) 1) 1) 1) 1, 2) 1) 2) 20 2 29 21 1 14 Streptococcus pneumoniae 356 moxifloxacin (MFLX), garenoxacin (GRNX) sitafloxacin (STFX), DX619 S. pneumoniae S. pneumoniae 60
More informationISOLATION AND POLYMERASE CHAIN REACTION DETECTION OF MYCOPLASMA PNEUMONIAE IN MALAYSIAN PATIENTS WITH RESPIRATORY TRACT INFECTIONS
ISOLATION AND POLYMERASE CHAIN REACTION DETECTION OF MYCOPLASMA PNEUMONIAE IN MALAYSIAN PATIENTS WITH RESPIRATORY TRACT INFECTIONS Tay ST, Habsah MY, Tan SC and Rohani MY Bacteriology Division, Institute
More informationMacrolides & Ketolides. Objectives. Protein Synthesis
Macrolides & Ketolides Elizabeth D. Hermsen, Pharm.D. Infectious Diseases Research Fellow University of Minnesota College of Pharmacy bjectives Participant should be able to explain macrolide/ketolide
More informationDissemination of Macrolide-Resistant Streptococcus pneumoniae Isolates Containing Both erm(b) and mef(a) in South Korea
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 2003, p. 5787 5791 Vol. 41, No. 12 0095-1137/03/$08.00 0 DOI: 10.1128/JCM.41.12.5787 5791.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationMacrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection
Journal of Antimicrobial Chemotherapy Advance Access published November 20, 2012 J Antimicrob Chemother doi:10.1093/jac/dks457 Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection
More informationApplication of real-time PCR for the detection of macrolide resistance in Belgian M. pneumoniae strains
Application of real-time PCR for the detection of macrolide resistance in Belgian M. pneumoniae strains K. Loens, S. C. Masha,, K. Lagrou, H. Goossens and M. Ieven Introduction (1) One of the smallest
More informationDistribution of emm type and antibiotic susceptibility of group A streptococci causing invasive and noninvasive disease
Journal of Medical Microbiology (2008), 57, 1383 1388 DOI 10.1099/jmm.0.2008/002642-0 Distribution of emm type and antibiotic susceptibility of group A streptococci causing invasive and noninvasive disease
More informationControl Sciences & Kitasato Institute for Life Sciences, Kitasato University Shirokane, Minato-ku, Tokyo , Japan
AAC Accepts, published online ahead of print on 30 March 2009 Antimicrob. Agents Chemother. doi:10.1128/aac.01716-08 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationRadiologic findings as a determinant and no effect of macrolide resistance on clinical course of Mycoplasma pneumoniae pneumonia
Yoon et al. BMC Infectious Diseases (2017) 17:402 DOI 10.1186/s12879-017-2500-z RESEARCH ARTICLE Radiologic findings as a determinant and no effect of macrolide resistance on clinical course of Mycoplasma
More informationMacrolide Resistance and Its Impacts on M. Pneumoniae Pneumonia in Children: Comparison of Two Recent Epidemics in Korea
Original Article Allergy Asthma Immunol Res. 2017 July;9(4):340-346. https://doi.org/10.4168/aair.2017.9.4.340 pissn 2092-7355 eissn 2092-7363 Macrolide Resistance and Its Impacts on M. Pneumoniae Pneumonia
More informationIn vitro and Intracellular Activities of Peptide Deformylase. Inhibitor GSK against Legionella pneumophila Isolates
AAC Accepts, published online ahead of print on 27 October 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.04006-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 In vitro
More informationUpdate on resistance and epidemiology of CAP pathogens in Asia. Cao Bin, MD
Update on resistance and epidemiology of CAP pathogens in Asia Cao Bin, MD Dept Infectious Diseases and Clinical Microbiology Beijing Chaoyang Hospital, Capital Medical University Outlines Resistance trends
More informationComparison of Two Laboratory Techniques for Detecting Mycoplasmas in Genital Specimens. Osama Mohammed Saed Abdul-Wahab, BSc, MSc, PhD*
Bahrain Medical Bulletin, Vol. 32, No. 4, December 200 Comparison of Two Laboratory Techniques for Detecting Mycoplasmas in Genital Specimens Osama Mohammed Saed Abdul-Wahab, BSc, MSc, PhD* Objective:
More informationChanges in the Distribution of Capsular Serotypes of Streptococcus pneumoniae Isolated from Adult Respiratory Specimens in Japan
ORIGINAL ARTICLE Changes in the Distribution of Capsular Serotypes of Streptococcus pneumoniae Isolated from Adult Respiratory Specimens in Japan Hisashi Shoji 1, Masayuki Maeda 2, Tetsuro Shirakura 3,
More informationACCEPTED. Comparison of disk diffusion and agar dilution methods for erythromycin and
AAC Accepts, published online ahead of print on January 00 Antimicrob. Agents Chemother. doi:./aac.000-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationORIGINAL ARTICLE. Clin Microbiol Infect 2002; 8:
ORIGINAL ARTICLE In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe I. A. Critchley
More informationAntibiotics.. Tetracyclines. Aminoglycoside. Macrolides. Chloramphenicol
Antibiotics. Tetracyclines. Aminoglycoside. Macrolides. Chloramphenicol Antibiotics as disturber with the biosynthesis of protein These antibiotics all target the bacterial ribosome and interfere in the
More informationJAC Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections
Journal of Antimicrobial Chemotherapy (1998) 41, Suppl. B, 69 73 JAC Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections G. Tatsis*, G.
More informationIn vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae
AAC Accepted Manuscript Posted Online 26 January 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.04127-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 In vitro assessment
More informationENG MYCO WELL D- ONE REV. 1.UN 29/09/2016 REF. MS01283 REF. MS01321 (COMPLETE KIT)
ENG MYCO WELL D- ONE MYCO WELL D-ONE System for the presumptive identification and antimicrobial susceptibility test of urogenital mycoplasmas, Gardnerella vaginalis, Trichomonas vaginalis, Candida albicans
More informationOUTLINE Laboratory Detection and Reporting of Streptococcus agalactiae
OUTLINE Laboratory Detection and Reporting of Streptococcus agalactiae I. Importance of prenatal screening strategies II. Past approaches Erik Munson Clinical Microbiology Wheaton Franciscan Laboratory
More informationIntroduction. Japan 3 Department of Radiology, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki, Japan
Tohoku J. Exp. Med., 2018, 246, 225-231 Rapid Molecular Identification for Mycoplasma pneumoniae 225 Implementation of Point-of-Care Molecular Diagnostics for Mycoplasma pneumoniae Ensures the Correct
More informationHigh dose amoxicillin for sinusitis
High dose amoxicillin for sinusitis Amoxil ( amoxicillin ) is a commonly used penicillin antibiotic. It is produced in tablets (500 mg 875 mg), capsules, chewable tablets and oral suspensions. 6-3-2018
More informationLaboratory Detection and Reporting of Streptococcus agalactiae
Laboratory Detection and Reporting of Streptococcus agalactiae Erik Munson Clinical Microbiology Wheaton Franciscan Laboratory Milwaukee, Wisconsin The presenter states no conflict of interest and has
More informationDevelopment of Multiple-Locus Variable-Number Tandem-Repeat Analysis for Molecular Typing of Mycoplasma pneumoniae
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2009, p. 914 923 Vol. 47, No. 4 0095-1137/09/$08.00 0 doi:10.1128/jcm.01935-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Development
More informationEffect of Azithromycin plus Rifampin versus That of Azithromycin Alone on the Eradication of Chlamydia pneumoniae
Antimicrobial Agents and Chemotherapy, June 1999, p. 1491-1493, Vol. 43, No. 6 0066-4804/99/$04.00+0 Copyright 1999, American Society for Microbiology. All rights reserved. Effect of Azithromycin plus
More informationACCEPTED ANTIPNEUMOCOCCAL ACTIVITY OF LBM415 COMPARED TO OTHER AGENTS. KLAUDIA KOSOWSKA-SHICK KIM L. CREDITO GLENN A. PANKUCH BONIFACIO DEWASSE
AAC Accepts, published online ahead of print on 20 November 2006 Antimicrob. Agents Chemother. doi:10.1128/aac.01150-06 Copyright 2006, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationEPIDEMIOLOGY OF MORAXELLA CATARRHALIS INFECTIONS AMONG THAI PATIENTS TREATED AT SIRIRAJ HOSPITAL, THAILAND DURING
EPIDEMIOLOGY OF MORAXELLA CATARRHALIS INFECTIONS AMONG THAI PATIENTS TREATED AT SIRIRAJ HOSPITAL, THAILAND DURING 2012-2015 Chanwit Tribuddharat and Somporn Srifuengfung Department of Microbiology, Faculty
More information* these authors contributed equally to the preparation of this report
AAC Accepts, published online ahead of print on June 00 Antimicrob. Agents Chemother. doi:0./aac.000-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationDiscrepancies in the recovery of bacteria from multiple sinuses in acute and chronic sinusitis
Journal of Medical Microbiology (2004), 53, 879 885 DOI 10.1099/jmm.0.45655-0 Short Communication Correspondence Itzhak Brook ib6@georgetown.edu Received 1 March 2004 Accepted 18 May 2004 Discrepancies
More informationTyping of ônh ôstaphylococcus epidermidis ôns ô Colonizing in Human Nares by Pulsed-Field Gel Electrophoresis
Microbiol. Immunol., 39(5), 315-319, 1995 Typing of ônh ôstaphylococcus epidermidis ôns ô Colonizing in Human Nares by Pulsed-Field Gel Electrophoresis Lan Hu*, Akiko Umeda, and Kazunobu Amako Department
More informationCases in employees. Cases. Day of onset (July)
Cases in employees 70 60 50 Cases 40 30 20 10 0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 Day of onset (July) 70 60 50 40 Cases 30 Cases in employees and visitors Employees Visitors 20 10 0 0 2 4 6 8
More informationNEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS. 20th Symposium (spring 2003) Thursday May 22nd 2003
NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS 20th Symposium (spring 2003) Thursday May 22nd 2003 The slides presented at this meeting are available on this site as "Web slide shows" and
More informationAmpicillin Resistance Mechanisms in Clinical Haemophilus influenzae: What is Happening in Portugal?
Ampicillin Resistance Mechanisms in Clinical Haemophilus influenzae: What is Happening in Portugal? M. Paula Bajanca-Lavado Haemophilus Reference Laboratory Infectious Disease Department National Institute
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationImportance of Atypical Pathogens of Community-Acquired Pneumonia
S35 Importance of Atypical Pathogens of Community-Acquired Pneumonia Joseph F. Plouffe Departments of Internal Medicine and Medical Microbiology and Immunology, Ohio State University College of Medicine,
More informationResistance to linezolid in enterococci and staphylococci referred to the national reference laboratory
Resistance to linezolid in enterococci and staphylococci referred to the national reference laboratory Dr Danièle Meunier, AMRHAI BSAC - Antimicrobial Susceptibility Testing User Days Oxazolidinone Linezolid
More informationRetapamulin Inhibition of Translation and ACCEPTED. 50S Ribosomal Subunit Formation in. Staphylococcus aureus Cells
AAC Accepts, published online ahead of print on 11 June 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.00475-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationGlobal challenge of antibiotic-resistant Mycoplasma genitalium. by author. Sabine Pereyre
Global challenge of antibiotic-resistant Mycoplasma genitalium Sabine Pereyre USC EA 3671 Mycoplasmal and chlamydial infections in humans INRA - University of Bordeaux -Bordeaux University Hospital National
More informationAntimicrobial chemotherapy of Mycoplasma genitaliumpositive. urethritis. Review
For reprint orders, please contact reprints@expert-reviews.com Antimicrobial chemotherapy of Mycoplasma genitaliumpositive non-gonococcal urethritis Expert Rev. Anti Infect. Ther. 10(7), 791 803 (2012)
More informationRespiratory Multiplex Array. Rapid, simultaneous detection of 22 bacterial and viral pathogens of the upper and lower respiratory tract
Rapid, simultaneous detection of 22 bacterial and viral pathogens of the upper and lower respiratory tract Rapid, simultaneous detection of 22 bacterial and viral pathogens within the upper and lower respiratory
More informationCharacterization of Mucoid and Non-Mucoid Streptococcus pneumoniae Isolated From Outpatients
Original Article Clinical Microbiology Ann Lab Med 2015;35:410-415 http://dx.doi.org/10.3343/alm.2015.35.4.410 ISSN 2234-3806 eissn 2234-3814 Characterization of Mucoid and Non-Mucoid Streptococcus pneumoniae
More informationBordeaux, France, from 1999 to 2002 and Description of Two tet(m)-positive Isolates of ACCEPTED
AAC Accepts, published online ahead of print on 19 November 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.00960-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationAbstract. Introduction
ORIGINAL ARTICLE BACTERIOLOGY In-Vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 years R. Krausse
More informationHigh-Dose Levofloxacin for the Treatment of Community-Acquired Pneumonia
High-Dose Levofloxacin for the Treatment of Community-Acquired Pneumonia Review Andrew F. Shorr, MD, MPH, FCCP Department of Medicine Pulmonary and Critical Care Medicine, Washington Hospital Center, Washington,
More informationINFECTION AND IMMUNITY, Sept. 1999, p Vol. 67, No. 9. Copyright 1999, American Society for Microbiology. All Rights Reserved.
INFECTION AND IMMUNITY, Sept. 1999, p. 4557 4562 Vol. 67, No. 9 0019-9567/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Identification of a New Variable Sequence in
More information(PFGE) Clostridium di$cile
2009 205 (PFGE) Clostridium di$cile 1) 3) 2) 2) 2) 2, 4) 5) 1) 2) 3) 4) 5) 21 5 22 21 8 31 2004 1 2008 12 5 Clostridium di$cile (C. di$cile) 340 248 A /B 141 (56.9) A /B 26 (10.5) A /B 81 (32.7) 136 (PFGE)
More informationThe macrolide family...
1 The macrolide family... erythromycin roxithromycin clarithromycin dirithromycin telithromycin azithromycin the last one!! josamycin spiramycin miocamycin 2 Erythromycin: activity Erythromycin A : mostly
More informationL élargissement des indica1ons des macrolides au long cours doit- il faire craindre l émergence de Mycoplasma pneumoniae résistant aux macrolides?
L élargissement des indica1ons des macrolides au long cours doit- il faire craindre l émergence de Mycoplasma pneumoniae résistant aux macrolides? écile Bébéar H de Bordeaux, France niversité de Bordeaux,
More informationWe determined the nucleotide sequence between 1,903 and 3,097 bp of pbp1a
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1998, p. 2267 2273 Vol. 42, No. 9 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology. All Rights Reserved. Association of a Thr-371 Substitution
More informationEmergence et impact clinique de la résistance aux antibiotiques chez Chlamydia trachomatis, Neisseria gonorrhoeae, les mycoplasmes
Emergence et impact clinique de la résistance aux antibiotiques chez Chlamydia trachomatis, Neisseria gonorrhoeae, les mycoplasmes Cécile Bébéar French National Center for bacterial STIs Bordeaux University
More informationActivity of Faropenem against Middle Ear Fluid Pathogens from Children with Acute Otitis Media in Costa Rica and Israel
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2007, p. 2230 2235 Vol. 51, No. 6 0066-4804/07/$08.00 0 doi:10.1128/aac.00049-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Activity
More informationChlamydia pneumoniae infection in adult patients with persistent cough
Journal of Medical Microbiology (2003), 52, 265 269 DOI 10.1099/jmm.0.04986-0 Chlamydia pneumoniae infection in adult patients with persistent cough Naoyuki Miyashita, Hiroshi Fukano, Koichiro Yoshida,
More informationANALYSIS OF MYCOPLASMA GENITALIUM STRAINS ISOLATED FROM PREGNANT WOMEN AT AN ACADEMIC HOSPITAL IN PRETORIA, SOUTH AFRICA
ANALYSIS OF MYCOPLASMA GENITALIUM STRAINS ISOLATED FROM PREGNANT WOMEN AT AN ACADEMIC HOSPITAL IN PRETORIA, SOUTH AFRICA Mafunise M 1, Le Roux MC 1, de Villiers BE 1, Ditsele RMM 1,2 1 Department of Microbiological
More informationA.F. GENITAL SYSTEM. ITEMS NECESSARY BUT NOT INCLUDED IN THE KIT A.F. GENITAL SYSTEM Reagent (ref ) Mycoplasma Transport Broth (ref.
A.F. GENITAL SYSTEM ENGLISH System for detection, count and susceptibility test of pathogenic urogenital microorganisms DESCRIPTION A.F. GENITAL SYSTEM is a 24-well system containing desiccated biochemical
More informationThe macrolide family...
1 The macrolide family... erythromycin roxithromycin clarithromycin dirithromycin telithromycin azithromycin josamycin spiramycin miocamycin 2 1 Erythromycin: activity Erythromycin A : mostly Gram (+)
More information97 80 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis
4 4 9 6 6 6 7 6 66 4 99.9.7 8. 7..8.4..7.9.. 4. 7.4 8.7 99 97 8 Streptococcus pneumoniae, Haemophilus influenzae, oraxella catarrhalis 4 4 64 7 9 7 89. RT PCR 4. 6 46. Key words: RT PCR I 6 6 46 64. 8.
More informationMicrobiology of Atypical Pneumonia. Dr. Mohamed Medhat Ali
Microbiology of Atypical Pneumonia Dr. Mohamed Medhat Ali Pneumonia P n e u m o n i a i s a n infection of the lungs that can be caused by viruses, bacteria, and fungi. Atypical! Pneumonia Symptoms. X-ray
More informationdoxycycline by using both tetracycline-susceptible and tetracycline-resistant (This work was presented in part at the 33rd Interscience
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 1994, p. 2628-2632 0066-4804/94/$04.00+0 Copyright X) 1994, American Society for Microbiology Vol. 38, No. 11 Susceptibilities of Mycoplasma hominis, Mycoplasma
More informationEfficacy of Antimicrobial Therapy for Mycoplasma genitalium Infections
SUPPLEMENT ARTICLE Efficacy of Antimicrobial Therapy for Mycoplasma genitalium Infections Lisa E. Manhart, 1,3 Jørgen Skov Jensen, 4 Catriona S. Bradshaw, 5 Matthew R. Golden, 2,3 and David H. Martin 6
More informationTELITHROMYCIN (KETEK ) A NEW ANTIMICROBIAL AGENT
Volume 19, Issue 12 September 2004 TELITHROMYCIN (KETEK ) A NEW ANTIMICROBIAL AGENT Christopher Cha, Pharm.D. Candidate Introduction Infections that invade the lower respiratory tract, such as community-acquired
More informationKlebsiella pneumoniae 21 PCR
2011 11 TEM-132 ESBL Klebsiella pneumoniae 1) 2) 1) 1) 3) 2) 1) 2) 3) 19 6 27 22 10 20 2003 4 2004 11 95 ceftazidime (CAZ) Klebsiella pneumoniae 21 PCR b- (ESBL) PCR (PFGE) PCR bla TEM-132 PFGE 19 TEM-132
More informationAntimicrobial susceptibility, carriage, children, day-care centres, orphanages, Streptococcus pneumoniae
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01505.x Antimicrobial resistance of nasopharyngeal pneumococci from children from day-care centres and orphanages in Russia: results of a unique prospective multicentre
More informationRésistance bactérienne au cours des Infections Sexuellement Transmissibles Cécile Bébéar
Résistance bactérienne au cours des Infections Sexuellement Transmissibles Cécile Bébéar French Na*onal Center for bacterial STIs Bordeaux University hospital, Bordeaux, France University of Bordeaux,
More informationEvaluation of the Oxoid Xpect Legionella test kit for Detection of Legionella
JCM Accepts, published online ahead of print on 6 May 2009 J. Clin. Microbiol. doi:10.1128/jcm.00397-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationRapid diagnosis of Mycoplasma pneumoniae infection in children by polymerase chain reaction
J Microbiol Immunol Infect. 2007;40:507-512 Liu et al Rapid diagnosis of Mycoplasma pneumoniae infection in children by polymerase chain reaction Fang-Ching Liu 1,2, Po-Yen Chen 2, Fang-Liang Huang 2,
More informationBeta-lactamase production should have no effect on Azithromycin activity.
AZIMEX Composition Azimex 250 Capsules Each capsule contains Azithromycin (as dihydrate) 250 mg Capsules & Powder Azimex 500 mg Capsules Each capsule contains Azithromycin (as dihydrate) 500 mg Azimex
More informationCharles Krasner, M.D. University of NV, Reno School of Medicine Sierra NV Veterans Affairs Medical Center
Charles Krasner, M.D. University of NV, Reno School of Medicine Sierra NV Veterans Affairs Medical Center Kathy Peters is a 63 y.o. patient that presents to your urgent care office today with a history
More informationM. Khanna and S. Visuri
The ProPneumo1 Assay: Detection of Chlamydophila pneumoniae, Mycoplasma pneumoniae, and an Internal Control Using Multiplex PCR on Multiple Real Time PCR Systems S. Dollhopf,, W. Majewski,, P. Douglass,
More informationRespiratory tract infections. Krzysztof Buczkowski
Respiratory tract infections Krzysztof Buczkowski Etiology Viruses Rhinoviruses Adenoviruses Coronaviruses Influenza and Parainfluenza Viruses Respiratory Syncitial Viruses Enteroviruses Etiology Bacteria
More informationMohammed Nooraldeen Al-Qattan (PhD)
Mohammed Nooraldeen Al-Qattan (PhD) Macrolides are macro lactone rings made up of 12 or more atoms, and usually contain one or more sugars. They are bacteriostatic agents that inhibit protein synthesis
More informationASSESMENT OF CRYOPRESERVATION SYSTEMS INFLUENCE ON THE SURVAVIAL OF E. COLI RECOMBINANT STRAINS
Lucrări ştiinńifice Zootehnie şi Biotehnologii, vol. 41(1) (2008), Timişoara ASSESMENT OF CRYOPRESERVATION SYSTEMS INFLUENCE ON THE SURVAVIAL OF E. COLI RECOMBINANT STRAINS TESTAREA INFLUENłEI SISTEMELOR
More informationAgainst Aerobic Gram-Negative Bacilli
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 1979, p. 6-6 0066-0/79/1-06/05$0.00/0 Vol., No. 6 In Vitro Activity of LY17935, a New 1-Oxa Cephalosporin, Against Aerobic Gram-Negative Bacilli DENNIS G. DELGADO,
More informationORIGINAL ARTICLE. S. D. Putnam 1, G. C. Gray 2, D. J. Biedenbach 3 and R. N. Jones 3
ORIGINAL ARTICLE Pharyngeal colonization prevalence rates for Streptococcus pyogenes and Streptococcus pneumoniae in a respiratory chemoprophylaxis intervention study using azithromycin S. D. Putnam 1,
More informationClinical efficacy and tolerability of grepafloxacin in lower respiratory tract infection
Clinical efficacy and tolerability of grepafloxacin in lower respiratory tract infection Sanford Chodosh Boston Veterans Administration Outpatient Clinic, Boston, Massachusetts, USA Studies in community-acquired
More informationIn Vitro Susceptibilities of Aerobic and Facultative Non-Spore- Forming Gram-Positive Bacilli to HMR 3647 (RU 66647) and 14 Other Antimicrobials
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1998, p. 1028 1033 Vol. 42, No. 5 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology In Vitro Susceptibilities of Aerobic and Facultative
More informationFollow this and additional works at:
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2014 Evaluation of a real-time PCR assay for simultaneous detection of Kingella kingae and Staphylococcus aureus
More informationIncreasing Genetic Relatedness of Ciprofloxacin-Resistant Streptococcus pneumoniae Isolated in Canada from 1997 to 2005
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2008, p. 1190 1194 Vol. 52, No. 3 0066-4804/08/$08.00 0 doi:10.1128/aac.01260-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Increasing
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.00869.x Invasive Streptococcus pneumoniae from Portugal: implications for vaccination and antimicrobial therapy I. Serrano, M. Ramirez, the Portuguese Surveillance
More informationValidation of Vitek version 7.01 software for testing staphylococci against vancomycin
Diagnostic Microbiology and Infectious Disease 43 (2002) 135 140 www.elsevier.com/locate/diagmicrobio Validation of Vitek version 7.01 software for testing staphylococci against vancomycin P.M. Raney a,
More informationThe macrolide family...
1 The macrolide family... erythromycin roxithromycin clarithromycin dirithromycin telithromycin azithromycin Coming soon!! josamycin spiramycin miocamycin 2 Erythromycin: mode of action 3 Erythromycin:
More informationMycoplasma genitalium: epidemiology, diagnostics and antimicrobial resistance
Mycoplasma genitalium: epidemiology, diagnostics and antimicrobial resistance Cécile Bébéar USC EA 3671 Mycoplasmal and chlamydial infections in humans INRA - University of Bordeaux Bordeaux University
More information1) 1) 1) 2) 2) (ICU) Key words: (ICU), ( ) 1 30 TEL: FAX: Vol. 17 No
2007 277 1) 1) 1) 2) 2) 3) 4) 5) 6) 1) 2) 3) 4) 5) 6) 18 10 17 19 8 20 16 7 1 (ICU) 20 2x 1.6 2.2 2SD 14 1 4 1 10 7 3 2 9 7.6; 95 2.37 24.62 6 4 5 1 DNA SpeI 9 2 A 7 B 2 A 3 B 1 ICU ICU 7 20 10 5 Key words:
More informationReport: antimicrobial resistance in commensal Enterococcus spp. from poultry, pigs, cows and veal calves
Veterinary and Agrochemical Research Centre Report: antimicrobial resistance in commensal Enterococcus spp. from poultry, pigs, cows and veal calves P. Butaye 1 Introduction Enterococci are regarded as
More informationMohammed Nooraldeen Al-Qattan (PhD)
Mohammed Nooraldeen Al-Qattan (PhD) Macrolides are macro lactone rings made up of 12 or more atoms, and usually contain one or more sugars. They are bacteriostatic agents that inhibit protein synthesis
More informationBeta-lactamase production should have no effect on Azithromycin activity.
AZIMEX Composition Azimex 250 Capsules Each capsule contains Azithromycin (as dihydrate) 250 mg Capsules Azimex 500 mg Capsules Each capsule contains Azithromycin (as dihydrate) 500 mg Action Azithromycin
More informationUpper Respiratory Infections. Mehreen Arshad, MD Assistant Professor Pediatric Infectious Diseases Duke University
Upper Respiratory Infections Mehreen Arshad, MD Assistant Professor Pediatric Infectious Diseases Duke University Disclosures None Objectives Know the common age- and season-specific causes of pharyngitis
More information